ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Therapy

FerGene gene therapy firm formed with $570 million in funding

by Lisa M. Jarvis
November 30, 2019 | APPEARED IN VOLUME 97, ISSUE 47

FerGene has launched with more than $570 million in funding from Ferring Pharmaceuticals and Blackstone Life Sciences to bring to market nadofaragene firadenovec, a bladder cancer gene therapy. Most of the money—$400 million—comes from Blackstone, an investment firm. Ferring licensed the adenovirally mediated interferon alfa-2b gene therapy last year from FKD Therapies, which had bought it from Merck & Co. in 2011. Ferring later filed for US approval of the treatment.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment